Eisai Plots A Meticulous Path To CMS Coverage For Lecanemab
US Exec Ivan Cheung Expects ‘More Open Access’ To Drug
Executive Summary
The company believes the Phase III Clarity AD results offer a high level of evidence that may convince the Centers for Medicare and Medicaid Services to change its stance on anti-amyloid antibodies for lecanemab.
You may also be interested in...
Lilly Does Not Expect A Quick Medicare Coverage Decision For Donanemab
Donanemab may receive accelerated approval for Alzheimer’s disease in early 2023, but Lilly will not approach CMS about Medicare coverage until mid-year when it has Phase III data – and even then does not expect a quick decision.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: US prospects for Sarepta’s DMD gene therapy; looking at price increases in the US; Eisai plans US CMS coverage for lecanemab; vaccine impact as China rolls back COVID zero policies; and ex-Novo Nordisk CEO Mads Øvlisen shares his career and life lessons.
Clearing Amyloid Provides Alzheimer’s Benefit, But With Risks That Need Careful Management
Eisai/Biogen’s lecanemab showed that reducing amyloid can slow Alzheimer’s disease progression, but prescribers will have to weigh the potential benefit versus safety risks on a patient-by-patient basis.